Cellectis (CLLS) Divestments (2022 - 2023)
Cellectis (CLLS) posted Divestments of -$18000.0 for Q2 2023, down 118.56% on a QoQ basis from $97000.0 in Q1 2023, and up 95.98% year-over-year from -$9184.5 in Q2 2022.
Cellectis (CLLS) has 2 years of Divestments data on file, last reported at -$18000.0 in Q2 2023.
- In Q2 2023, Divestments rose 95.98% year-over-year to -$18000.0; the TTM figure through Dec 2023 stood at $79000.0 (up 117.71% YoY), while the FY2023 annual figure was $79000.0, up 117.71% from the prior year.
- Divestments declined to -$18000.0 in Q2 2023, from $97000.0 in the prior quarter.
- Across five years, Divestments topped out at $177000.0 in Q3 2022 and bottomed at -$448000.0 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -18,000.00 |
| Mar 31, 2023 | 97,000.00 |
| Dec 31, 2022 | 121,000.00 |
| Sep 30, 2022 | 177,000.00 |
| Jun 30, 2022 | -448,000.00 |
| Mar 31, 2022 | -296,000.00 |